Published 4 days ago • loading... • Updated 4 days ago

Second-Line Treatment for Gastric Adenocarcinoma

Summary by cancernetwork.com

Panelists discuss how second-line treatments for gastric adenocarcinoma provide survival advantages, improved quality of life, and opportunities for personalized therapy based on molecular profiling and prior treatment response.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

5 Articles

All

Left

Center

Right

cancernetwork.com

Second-Line Treatment for Gastric Adenocarcinoma

4 days ago

Read Full Article

The Objective | Periodismo ethos

+2 Reposted by 2 other sources

BeiGene begins a new era in Spain with its takeoff in solid tumors

The Ministry of Health will tomorrow incorporate two new indications of tislelizumab into the portfolio of the National Health System (NSS), the second drug of BeiGene approved in Spain. Specifically, one for the first-line treatment of gastric adenocarcinoma or gastroesophageal junction (CG/CUGE) and one for squamous cell carcinoma of the esophagus (SCEE) in combination with platinum-based chemotherapy. These two drugs are added to those alread…

4 days ago·Madrid, Spain

Read Full Article

redaccionmedica.com

Beigene reaffirms in Spain and promotes clinical collaboration in cancer

Four years ago Beigene landed in Spain and, since then, his commitment to our country has been more than palpable. In addition to arriving with new drugs, they already have two approved with funding in the National Health System (NSS), they have also brought a great defense of clinical research, deploying in Spain many of these trials. This Monday they have presented their strategy in solid tumors, their next name change to Beone and their inter…

4 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year